Zobrazeno 1 - 10
of 1 834
pro vyhledávání: ''
Autor:
Hemant S. Murthy, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Farah Yassine, Arni Kumar, Mahmoud Aljurf, Katelyn Keller, Andre Fernandez, Tea Reljic, Madiha Iqbal
Publikováno v:
Bone Marrow Transplantation. 57:65-71
Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for patients with malignant and benign hematologic conditions. Graft-versus-host disease (GVHD) is a known complication of allo-HCT that results in significant morbidity
Autor:
Liat Shargian-Alon, Moshe Yeshurun, Hira S. Mian, Hillard M. Lazarus, Shaji Kumar, Baldeep Wirk, Sagar S. Patel, Patrick Hagen, Sunita Nathan, Ricardo D. Parrondo, Naresh Bumma, Leona Holmberg, Mark A. Schroeder, Cindy Lee, Oren Pasvolsky, Nina Shah, Uri Rozovski, Saad Z. Usmani, Noel Estrada-Merly, Arnon Nagler, Trent P Wang, Taiga Nishihori, Muzaffar H. Qazilbash, Rahul Banerjee, Kevin C. Miller, Robert Peter Gale, Nasheed Hossain, Raphael Fraser, Amer Assal, Anita D'Souza
Publikováno v:
Bone Marrow Transplant
The role of maintenance therapy after high-dose chemotherapy and first autologous transplantation in multiple myeloma (MM) is well established. We explored the effect of maintenance therapy on outcomes after salvage second autologous hematopoietic ce
Autor:
Teresa L. Ramos, Alfonso Rodríguez-Gil, José Antonio Pérez-Simón, Melanie Nufer, Teresa Caballero-Velázquez, Estefanía García-Guerrero, María Victoria Barbado, Rocío Caracuel-García, María José Robles-Frías
Publikováno v:
Bone Marrow Transplantation
Digital.CSIC. Repositorio Institucional del CSIC
instname
Digital.CSIC. Repositorio Institucional del CSIC
instname
In this study, we aimed to modify the immune response in the long term after allogeneic bone marrow transplantation (allo-BMT) by using the proteasome inhibitor ixazomib (IXZ) at the late stages of the post-transplant period. This approach facilitate
Publikováno v:
Bone Marrow Transplantation
Relapse after allogeneic stem cell transplant in unfavorable-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) portends a poor prognosis. We conducted a single-center phase I dose-escalation study with lenalidomide mainte
Autor:
Ikhlaaq Ahmed, Andrea Hodgkinson, Rebecca Bishop, Ram Malladi, Jane Nunnick, Shamyla Siddique, Aimee Jackson, Fiona L Dignan, Mohamed Elhaneid, Graham McIlroy, Paul Moss, Charles Craddock, Rachel Protheroe
Publikováno v:
Bone Marrow Transplantation. 56:2948-2955
Chronic graft-versus-host disease (cGvHD) is a major cause of non-relapse morbidity and mortality following allogeneic stem cell transplant. Over half of patients with moderate or severe cGvHD fail to respond adequately to first-line treatment with s
Autor:
Eugenia Abella, Laura Rosiñol, Mercedes Gironella, Alicia Senín, Carlos Fernández de Larrea, Alfons Soler, Cristina Motlló, Randa Ben-Azaiz, MT Cibeira, Jordi López-Pardo, Rodrigo Martino, Marta Canet, Josep Ma Martí, Jorge Sierra, Miquel Granell, Albert Oriol, Anna Barata, Antoni Garcia-Guiñon
Publikováno v:
BONE MARROW TRANSPLANTATION
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
Bone Marrow Transplantation
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
Bone Marrow Transplantation
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Return to work (RTW) is a marker of functional recovery in cancer patients, with quality of life, financial and social implications. We investigated frequency and factors associated with RTW in a cohort of patients younger than 66 years, with newly d
Autor:
Mark A. Schroeder, Steven M. Devine, Yi-Bin Chen, Andrejus Parfionovas, Yngvar Fløisand, Syed Quadri, Dominik Selleslag, Chunlin Chen, Ibrahim Yakoub-Agha, Patrice Chevallier, Mona Akbari, Mohamad Mohty, Johan Jansson, Anne S. Renteria
Publikováno v:
Bone Marrow Transplantation
Bone Marrow Transplantation, In press, ⟨10.1038/s41409-021-01356-0⟩
Bone Marrow Transplantation, Nature Publishing Group, In press, ⟨10.1038/s41409-021-01356-0⟩
Bone Marrow Transplantation, In press, ⟨10.1038/s41409-021-01356-0⟩
Bone Marrow Transplantation, Nature Publishing Group, In press, ⟨10.1038/s41409-021-01356-0⟩
Steroid-refractory (SR) acute graft-versus-host disease (aGvHD) remains a significant complication after allogeneic hematopoietic cell transplantation. Systemic corticosteroids are first-line therapy for aGvHD, but apart from ruxolitinib, there are n
Autor:
Dongyun Yang, Stephen J. Forman, Haris Ali, Andrew S. Artz, Paul Koller, Anthony S. Stein, Ibrahim Aldoss, Sanjeet Dadwal, Guido Marcucci, Ahmed Aribi, Monzr M. Al Malki, Stephanie Mac, Jason Chen, Thai Cao, Shukaib Arslan, Vinod Pullarkat, Amandeep Salhotra, Ryotaro Nakamura, Dat Ngo, Karamjeet S. Sandhu, Nicole Karras
Publikováno v:
Bone Marrow Transplantation. 56:2464-2470
Currently, there is no consensus on best practices to prevent hemorrhagic cystitis (HC) in patients receiving posttransplant cyclophosphamide (PTCy). We retrospectively reviewed 194 patients undergoing their first hematopoietic cell transplant (HCT)
Autor:
M. Fung, Nosha Farhadfar, Joseph Pidala, Lisette M. Acevedo, Edmund K. Waller, Trent P Wang, Mark A. Schroeder, Jeremy Pantin, John Koreth, Cherie Tracy Ng, Marco Mielcarek, Alison W. Loren, Gabrielle Meyers, Joel Rothman, Krishna R. Polu, Stephen Connelly, Ryotaro Nakamura, Corey Cutler, George Chen, Daanish Hoda, Sarah Anand
Publikováno v:
Bone Marrow Transplantation. 56:369-374
Background: CD6 is a co-stimulatory receptor predominantly expressed on T cells. CD6high CD4+ T cells were recently shown to drive Th1/Th17 immune responses in inflammatory bowel disease and may have a similar role in acute graft-versus-host disease
Autor:
Anja M. Jansen-Hoogendijk, Astrid G. S. van Halteren, Robbert G. M. Bredius, Maarten J. D. van Tol, Alexander B. Mohseny, Lisa V E Oostenbrink, Emma S. Pool, Arjan C. Lankester, Cornelia M. Jol-van der Zijde, Frans J. Smiers, Carly Vervat, Marco W. Schilham
Publikováno v:
Bone Marrow Transplantation. SPRINGERNATURE
Bone Marrow Transplantation
Bone Marrow Transplantation
The use of HLA-mismatched (un)related donors is historically associated with a higher incidence of transplant-related complications and mortality. However, the use of such donors may overcome the limited availability of HLA-matched donors for patient